ENVERIC BIOSCIENCES, INC. : Regulation FD Disclosure, Financial Statements and Exhibits (form 8-K)

Item 7.01. Regulation FD Disclosure.

On January 18, 2022, Enveric Biosciences, Inc. (the "Company") issued a press release containing a letter from the Company's CEO providing a 2021 year in review and 2022 outlook. A copy of such press release is attached hereto as Exhibit 99.1 and is incorporated by reference herein.

In accordance with General Instruction B.2 of Form 8-K, the information in this Current Report on Form 8-K, including Exhibit 99.1, is being furnished pursuant to Item 7.01 and shall not be deemed "filed" for the purposes of Section 18 of the Exchange Act, or otherwise subject to the liabilities of that section, nor shall it be deemed incorporated by reference in any filing under the Exchange Act or the Securities Act of 1933, as amended, except as shall be expressly set forth by reference in such a filing.

Item 9.01. Financial Statements and Exhibits.

(d) Exhibits.



Exhibit No.   Description

99.1            Press Release, issued January 18, 2022 (furnished pursuant to Item
              7.01)
104           Cover Page Interactive Data File (embedded within the Inline XBRL
              document)




                                     * * *

© Edgar Online, source Glimpses